--Barclays Adjusts Price Target on Reata Pharmaceuticals to $98 From $90, Keeps Overweight Rating

--Barclays Adjusts Price Target on Reata Pharmaceuticals to $98 From $90, Keeps Overweight Rating

MT Newswires · 05/11/2023 05:04

Please log in to view news